REG - AstraZeneca PLC - Result of AGM

AstraZenecaAnnouncement

27/04/2023 17:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230427:nRSa7648Xa&default-theme=true

RNS Number : 7648X  AstraZeneca PLC  27 April 2023

27 April 2023 17:30 BST

 

Results of Annual General Meeting held on 27 April 2023

 

AstraZeneca PLC announced the results of the voting at its Annual General
Meeting (AGM) today. As proposed in the Notice of AGM, all Resolutions were
decided by poll vote. Resolutions 9 - 13 were passed as special resolutions;
all other resolutions were passed as ordinary resolutions.

 

     Resolution                                                                   Votes for      % of votes cast  Votes against  % of votes cast  Votes cast in total  Total votes cast as a % of issued share capital  Votes withheld
 1   To receive the Company's Accounts, the Reports of the Directors and Auditor  1,264,644,490  99.80            2,524,193      0.20             1,267,168,683        81.76                                            2,068,894
     and the Strategic Report for the year ended 31 December 2022
 2   To confirm dividends                                                         1,254,919,878  98.92            13,679,112     1.08             1,268,598,990        81.85                                            638,576
 3   To reappoint PricewaterhouseCoopers LLP as Auditor                           1,260,792,714  99.39            7,718,080      0.61             1,268,510,794        81.85                                            726,500
 4   To authorise the Directors to agree the remuneration of the Auditor          1,268,225,831  99.98            270,095        0.02             1,268,495,926        81.85                                            741,641
 5a  To re-elect Michel Demaré as a Director                                      1,241,496,328  97.88            26,829,809     2.12             1,268,326,137        81.84                                            911,430
 5b  To re-elect Pascal Soriot as a Director                                      1,260,336,535  99.37            7,986,485      0.63             1,268,323,020        81.83                                            914,729
 5c  To re-elect Aradhana Sarin as a Director                                     1,265,264,711  99.76            3,062,442      0.24             1,268,327,153        81.84                                            910,131
 5d  To re-elect Philip Broadley as a Director                                    1,259,273,602  99.29            9,043,851      0.71             1,268,317,453        81.83                                            920,114
 5e  To re-elect Euan Ashley as a Director                                        1,268,022,043  99.98            282,266        0.02             1,268,304,309        81.83                                            924,629
 5f  To re-elect Deborah DiSanzo as a Director                                    1,267,959,577  99.97            349,778        0.03             1,268,309,355        81.83                                            926,746
 5g  To re-elect Diana Layfield as a Director                                     1,268,027,536  99.98            274,653        0.02             1,268,302,189        81.83                                            935,378
 5h  To re-elect Sheri McCoy as a Director                                        1,241,492,257  97.88            26,842,094     2.12             1,268,334,351        81.84                                            903,216
 5i  To re-elect Tony Mok as a Director                                           1,261,574,735  99.97            322,367        0.03             1,261,897,102        81.42                                            7,338,922
 5j  To re-elect Nazneen Rahman as a Director                                     1,266,284,904  99.85            1,870,104      0.15             1,268,155,008        81.82                                            1,082,559
 5k  To re-elect Andreas Rummelt as a Director                                    1,268,030,928  99.98            285,793        0.02             1,268,316,721        81.83                                            920,846
 5l  To re-elect Marcus Wallenberg as a Director                                  1,026,140,887  80.93            241,825,345    19.07            1,267,966,232        81.81                                            1,263,367
 6   To approve the Annual Report on Remuneration for the year ended 31 December  1,195,261,107  94.23            73,125,360     5.77             1,268,386,467        81.84                                            850,827
     2022
 7   To authorise limited political donations                                     1,228,047,446  97.76            28,189,687     2.24             1,256,237,133        81.06                                            13,000,783
 8   To authorise the Directors to allot shares                                   1,166,174,071  91.95            102,088,563    8.05             1,268,262,634        81.83                                            966,964
 9   To authorise the Directors to disapply pre-emption rights                    1,193,686,193  94.15            74,121,064     5.85             1,267,807,257        81.80                                            1,430,310
 10  To authorise the Directors to further disapply pre-emption rights for        1,153,850,923  91.25            110,689,108    8.75             1,264,540,031        81.59                                            4,697,303
     acquisitions and specified capital investments
 11  To authorise the Company to purchase its own shares                          1,254,158,039  98.92            13,730,760     1.08             1,267,888,799        81.81                                            1,348,767
 12  To reduce the notice period for general meetings                             1,178,311,157  93.41            83,098,807     6.59             1,261,409,964        81.39                                            7,827,602
 13  To adopt new Articles of Association of the Company                          1,258,637,857  99.26            9,327,063      0.74             1,267,964,920        81.81                                            1,272,646

 

A copy of the resolutions passed at the AGM (other than resolutions concerning
ordinary business) has been submitted to the National Storage Mechanism for
publication, and will shortly be available for inspection
at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

 Issued capital

As at 25 April 2023, the number of issued shares of the Company was
1,549,856,584 ordinary shares, which was the total number of shares entitling
the holders to attend and vote for or against all of the resolutions at the
AGM. In accordance with the Company's Articles of Association, on a poll every
member present in person or by proxy has one vote for every share held.

 

AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on Twitter @AstraZeneca (http://www.twitter.com/AstraZeneca) .

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGPPUQCCUPWGAM